SS-31 (Elamipretide) Animal Study Design: Models, Controls, and Endpoints in the Published Literature

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that has been evaluated across a range of rodent disease models, and the published literature offers a useful picture of how such animal studies have been structured. This guide summarises study design features — model selection, randomisation and control arms, treatment duration, and endpoint panels — as reported in the retrieved research record. All findings are described in terms of the model in which they were observed. One of the more fully specified designs comes from a rat model of heart failure with preserved ejection fraction (HFpEF), in which female Zucker fatty spontaneously hypertensive heart failure F1 hybrid lean rats (n=10) served as controls and obese rats (n=24) constituted the HFpEF group [1]. At 20 weeks of age the HFpEF animals were randomised to receive either NaCl vehicle (n=12) or elamipretide (n=12) for 12 weeks, after which skeletal muscle tissue was collected [1]. The endpoint panel in that animal study spanned whole-muscle force, single-fiber mechanics, mitochondrial respiration, histology, and molecular analyses, with reported outcomes including cardiolipin levels, tafazzin expression, titin phosphorylation, fiber cross-sectional area, and oxidative stress markers [1]. This combination of a genetically defined disease strain, an age-matched lean control, vehicle randomisation, and paired functional-plus-mitochondrial readouts recurs as a template across the animal literature. Model choice in these studies is closely tied to the pathology under investigation. An aged, hypertensive mouse model was used to test whether SS-31 altered cerebral microhemorrhage susceptibility, with brain sections labeled by diaminobenzidine and digitised on a slide-scanner platform [2]. In that animal study, SS-31 treatment did not significantly mitigate hypertension-induced cerebral microhemorrhage burden in aged mice, and the authors emphasised the accompanying machine-learning imaging pipeline — a random forest classifier with color space transformation, benchmarked against manual counting and color deconvolution — as the methodological contribution [2]. Reporting a null functional result alongside a validated quantification method is itself a design consideration in preclinical screening work [2]. Acute-injury designs use different timing and outcome structures. In a rat cardiac arrest study, animals were randomised to two groups and, after 25 minutes of asphyxia-induced cardiac arrest, resuscitated with or without SS-31 using cardiopulmonary bypass, with survival followed for an additional 4.5 hours under haemodynamic monitoring and blood gas sampled at multiple time points [5]. Five of 10 rats survived in the SS-31 group versus 1 of 10 controls (p=0.026), and blood lactate at 90 minutes after resuscitation was lower in the SS-31 rats (4.29±2.5 mmol/L) than in controls (7.36±3.1 mmol/L, p=0.026) [5]. In a focal ischemic stroke study, mice were subjected to either 30-minute transient or permanent ischemia, with CD36-deficient mice and a parallel cohort receiving vehicle or 5 mg/kg SS-31; MCP-1 and CCR2 mRNA, infarct volume, and percent hemispheric swelling were measured, and attenuation was observed in the transient but not the permanent model [7]. That paired transient/permanent design illustrates how including a second injury variant can constrain the interpretation of a positive result [7]. Several animal studies embed SS-31 as a mechanistic probe rather than as the sole intervention. In a murine burn-and-infection model of Pseudomonas aeruginosa, gastrocnemius muscle was interrogated 5 days post-infection for ATP generation, oxidative phosphorylation, antioxidant response, reactive oxygen species, and mitochondrial DNA oxidative damage, with the mitochondrial-targeted peptide SS-31 and a small-molecule MvfR inhibitor used in parallel as rescue arms against the wild-type PA14 strain [6]. In a rat mechanical ventilation study, SS-31 was used to test whether preventing mitochondrial reactive oxygen species emission was necessary for ventilation-induced diaphragm weakness, comparing SS-31-treated with saline-treated ventilated animals across mitochondrial function, oxidative stress, protease activation, myofiber atrophy, and contractile dysfunction [9]. Using the compound to establish cause and effect for a specific reactive oxygen species source is an explicit design rationale in that report [9]. Age and dietary challenge have also been used as design variables. In male CB6F1 mice, a 60% kcal high-sucrose diet was given to 24-month-old animals against age-matched chow-fed controls, with cardiac hypertrophy detected by week 1 and persisting across 4 weeks [8]. A follow-up arm treated old and young mice with elamipretide or saline for 2 weeks, with high-sucrose diet provided only in the final week; age-related cardiac hypertrophy worsened on the diet and was prevented by elamipretide in old mice, while the diet produced no detectable hypertrophy in young mice, and mitochondrial respiration and reactive oxygen species production varied by age but were not significantly affected by diet or elamipretide in that study [8]. Including both young and old cohorts separates age-dependent from age-independent effects [8]. In vitro work provides the mechanistic and dose-ranging context that animal designs draw on. Human tenocytes from healthy hamstring and degenerative supraspinatus tendon biopsies (9 patients each) were assigned to four groups — healthy, healthy plus 1 μM SS-31 for 72 hours, degenerative, and degenerative plus SS-31 — with mitochondrial membrane potential, transmission electron microscopy morphology, reactive oxygen species, superoxide dismutase activity, gene expression, and viability as endpoints [3]. A separate structure-activity study benchmarked three tetrapeptide analogs against SS-31 using NMR and molecular dynamics structural models, cardiolipin-containing membrane binding assays, membrane surface charge measurements, and mammalian cell culture stress models, reporting that analogs differed in their ability to restore mitochondrial membrane potential, preserve ATP content, and promote cell survival [4]. These cell and biophysical designs define the comparator peptides and mechanistic endpoints that in vivo studies subsequently test [4].